Showing results (331-340 of 376) with videos related to
Sort By:
Pageof 38
Diabetic Medicine : a Journal of the British Diabetic Association|August 13, 1999
Increased sympathetic activity during sleep and nocturnal hypertension in Type 2 diabetic patients with diabetic nephropathyF S Nielsen, H P Hansen, P Jacobsen, et al.Diabetologia|October 1, 2010
Increased serum potassium affects renal outcomes: a post hoc analysis of the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) trialY Miao, D Dobre, H J Lambers Heerspink, et al.Kidney International|March 14, 2008
Time course of the antiproteinuric and antihypertensive effects of direct renin inhibition in type 2 diabetesF Persson, P Rossing, K J Schjoedt, et al.Diabetic Medicine : a Journal of the British Diabetic Association|September 3, 2011
Patient satisfaction and barriers to initiating real-time continuous glucose monitoring in early pregnancy in women with diabetesA L Secher, A B Madsen, L Ringholm, et al.Diabetes|March 31, 1998
Predisposition to essential hypertension and development of diabetic nephropathy in IDDM patientsJ A Fagerudd, L Tarnow, P Jacobsen, et al.Diabetologia|July 4, 2012
Higher plasma high-mobility group box 1 levels are associated with incident cardiovascular disease and all-cause mortality in type 1 diabetes: a 12 year follow-up studyJ W M Nin, I Ferreira, C G Schalkwijk, et al.Journal of Human Hypertension|March 27, 2015
Pulse pressure is not an independent predictor of outcome in type 2 diabetes patients with chronic kidney disease and anemia--the Trial to Reduce Cardiovascular Events with Aranesp Therapy (TREAT)S Theilade, B Claggett, T W Hansen, et al.Scandinavian Journal of Clinical and Laboratory Investigation|February 1, 1991
Acute cardiovascular effects of insulin in hyperglycaemic type I diabeticsP C Gøtzsche, H Kelbaek, S F Vissing, et al.Tissue Antigens|October 1, 1986
HLA associations in insulin-dependent diabetes: search for heterogeneity in different groups of patients from a homogeneous populationA Svejgaard, B K Jakobsen, P Platz, et al.Diabetologia|May 19, 2010
Optimal antiproteinuric dose of aliskiren in type 2 diabetes mellitus: a randomised crossover trialF Persson, P Rossing, H Reinhard, et al.Pageof 38